ROCKET PHARMACEUTICALS, INC. (RCKT) Form 10-Q — Aug 10, 2026
Rocket Pharmaceuticals swung to Q2 2026 net income of $123.2 million ($1.09 basic EPS) from a $68.9 million loss a year earlier, driven by a one-time $178.2 million gain on the $180 million sale of its Rare Pediatric Disease Priority Review Voucher, which closed in June 2026. The company ended the quarter with $283.7 million in cash, equivalents and investments and believes it has sufficient capital to fund operations into the second quarter of 2028, even after burning $85.0 million of operating cash in the first half; a $100 million at-the-market program with Cantor Fitzgerald remains untapped.
Key figures
- Eps
- 1.09 basic / 1.08 diluted (Q2 2026); 0.67 basic / 0.66 diluted (H1 2026)
- Revenue
- 0
- Net Income
- 123.2 million (Q2 2026) vs. loss of 68.9 million (Q2 2025)
- Total Assets
- 423.1 million
- Cash Position
- 224.5 million cash and equivalents; 283.7 million including investments (June 30, 2026)
- Shares Outstanding
- 109774597
- Atm program
- up to 100 million with Cantor Fitzgerald; no shares sold through June 30, 2026
- Cash runway
- into the second quarter of 2028
- Prv sale gain
- 178.2 million
- Prv sale price
- 180 million (agreed April 2026, closed June 2026)
- Ga expense q2 2026
- 17.4 million (down from 25.0 million in Q2 2025)
- Accumulated deficit
- 1.37 billion as of June 30, 2026
- Rnd expense q2 2026
- 29.5 million (down from 42.7 million in Q2 2025)
- Six month net income
- 75.6 million (H1 2026) vs. loss of 130.3 million (H1 2025)
- Option exchange program
- 1,376,937 option shares cancelled (94.6% of eligible); 686,137 replacement options granted at $3.00
- Finance lease liabilities
- 21.3 million total (no traditional debt)
- Operating cash burn h1 2026
- -85.0 million
- Net capital raised since inception
- approximately 1.2 billion
Price after filing
Close on the filing date to close N calendar days later (from $3.61). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.